A pipeline of possibility

Agios has a proven track record of leveraging our expertise in cellular metabolism to discover new therapeutic approaches and bring innovative medicines to patients in need.

Building on our core capabilities, we are advancing a robust pipeline focused on genetically defined diseases. At our core, we’re guided by a deep respect for science and a passion to change patients’ lives for the better.

Pipeline

Candidate

Drug Discovery

Early Stage Clinical Development

Late Stage Clinical Development

Regulatory Submission

Approved

Mitapivat

(PK Activator)

AG-946

(PK Activator)

Preclinical

Our science

For nearly 15 years, Agios has been committed to furthering the science of cellular metabolism to identify therapies for patients with unmet needs.

Our deep and differentiated understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together.

Go Deeper

Recent
publications

For investors

Agios is committed to creating value for shareholders by creating value for patients and healthcare providers. Find out how in our latest press releases and SEC filings, upcoming events and other resources for investors.

Learn More

We’re hiring! Come join a team where strong personal connections drive breakthroughs that make a difference in patients’ lives.